Drug Type Monoclonal antibody |
Synonyms EU 101, EU-101, NOV-1801 |
Target |
Action agonists |
Mechanism 4-1BB agonists(Tumor necrosis factor receptor superfamily member 9 agonists) |
Therapeutic Areas |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization |
Drug Highest PhasePhase 1/2 |
First Approval Date- |
Regulation- |



| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Colorectal Cancer | Phase 2 | South Korea | 31 May 2021 | |
| Locally Advanced Malignant Solid Neoplasm | Phase 2 | United States | 31 May 2021 | |
| metastatic non-small cell lung cancer | Phase 2 | United States | 31 May 2021 | |
| Metastatic Renal Cell Carcinoma | Phase 2 | United States | 31 May 2021 | |
| Prostatic Cancer | Phase 2 | United States | 31 May 2021 | |
| Neoplasms | Preclinical | China | 01 Sep 2017 |






